Top

Published in:

Open Access 12-12-2022 | Etanercept | Review

Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors

Authors: Anaïs Makos, J. H. Kuiper, O. Kehoe, R. Amarasena

Published in: Inflammopharmacology | Issue 1/2023

Abstract

Psoriatic arthritis (PsA) is a chronic and painful inflammatory immune-mediated disease. It affects up to 40% of people with psoriasis and it is associated with several comorbidities such as obesity, diabetes, metabolic syndrome, and hypertension. PsA is difficult to diagnose because of its diverse symptoms, namely axial and peripheral arthritis, enthesitis, dactylitis, skin changes, and nail dystrophy. Different drugs exist to treat the inflammation and pain. When patients do not respond to conventional drugs, they are treated with biologic drugs. Tumour necrosis factor inhibitors (TNFi’s) are commonly given as the first biologic drug; beside being expensive, they also lack efficacy in 50% of patients. A biomarker predicting individual patient’s response to TNFi would help treating them earlier with an appropriate biologic drug. This study aimed to review the literature to identify potential biomarkers that should be investigated for their predictive ability. Several such biomarkers were identified, namely transmembrane TNFα (tmTNF), human serum albumin (HSA) and its half-life receptor, the neonatal Fc receptor (FcRn) which is also involved in IgG lifespan; calprotectin, high mobility group protein B1 (HMGB1) and advanced glycation end products (AGEs) whose overexpression lead to excessive production of pro-inflammatory cytokines; lymphotoxin α (LTα) which induces inflammation by binding to TNF receptor (TNFR); and T helper 17 (Th17) cells which induce inflammation by IL-17A secretion.

Ademowo OS et al (2016) Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis. Ann Rheum Dis 75(1):234–241. https://doi.org/10.1136/annrheumdis-2014-205417CrossRefPubMed

Anandarajah AP, Ritchlin CT (2003) Etanercept in psoriatic arthritis. Expert Opin Biol Ther 3(1):169–177. https://doi.org/10.1517/14712598.3.1.169CrossRefPubMed

Andersson U, Tracey KJ (2011) HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol 29:139–162. https://doi.org/10.1146/annurev-immunol-030409-101323CrossRefPubMedPubMedCentral

Aochi S et al (2011) Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages. J Am Acad Dermatol 64(5):879–887. https://doi.org/10.1016/j.jaad.2010.02.049CrossRefPubMed

Arias MT et al (2015) A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. Clin Gastroenterol Hepatol 13(3):531–538. https://doi.org/10.1016/j.cgh.2014.07.055CrossRefPubMed

Atreya R et al (2014) In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med 20(3):313–318. https://doi.org/10.1038/nm.3462CrossRefPubMedPubMedCentral

Ben Mkaddem S, Benhamou M, Monteiro RC (2019) Understanding Fc receptor involvement in inflammatory diseases: from mechanisms to new therapeutic tools. Front Immunol 10:811. https://doi.org/10.3389/fimmu.2019.00811CrossRefPubMedPubMedCentral

Bettiga A et al (2019) The modern western diet rich in advanced glycation end-products (AGEs): an overview of its impact on obesity and early progression of renal pathology. Nutrients 11(8):1748. https://doi.org/10.3390/nu11081748CrossRefPubMedPubMedCentral

Bianchi ME (2007) DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 81(1):1–5. https://doi.org/10.1189/jlb.0306164CrossRefPubMed

Biscetti F et al (2017) The role of high-mobility group box-1 and its crosstalk with microbiome in rheumatoid arthritis. Mediators Inflamm. https://doi.org/10.1155/2017/5230374CrossRefPubMedPubMedCentral

Blauvelt A, Chiricozzi A (2018) The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol 55(3):379–390. https://doi.org/10.1007/s12016-018-8702-3CrossRefPubMedPubMedCentral

Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473(2):139–146. https://doi.org/10.1016/j.abb.2008.03.018CrossRefPubMedPubMedCentral

Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214(2):149–160. https://doi.org/10.1002/path.2287CrossRefPubMed

Bunte K, Beikler T (2019) Th17 cells and the IL-23/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci 20(14):E3394. https://doi.org/10.3390/ijms20143394CrossRef

Candia L et al (2007) Toll-like receptor-2 expression is upregulated in antigen-presenting cells from patients with psoriatic arthritis: a pathogenic role for innate immunity? J Rheumatol 34(2):374–379PubMed

Cecchinato V et al (2018) Redox-mediated mechanisms fuel monocyte responses to CXCL12/HMGB1 in active rheumatoid arthritis. Front Immunol. https://doi.org/10.3389/fimmu.2018.02118CrossRefPubMedPubMedCentral

Chandran V et al (2013) Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J Rheumatol 40(6):866–871. https://doi.org/10.3899/jrheum.121162CrossRefPubMed

Chen M, Dai S-M (2020) A novel treatment for psoriatic arthritis: Janus kinase inhibitors. Chin Med J 133(8):959–967. https://doi.org/10.1097/CM9.0000000000000711CrossRefPubMedPubMedCentral

Chimenti MS et al (2013) Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Dev Ther 7:339–348. https://doi.org/10.2147/DDDT.S31658CrossRef

Chiricozzi A, Krueger JG (2013) IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 22(8):993–1005. https://doi.org/10.1517/13543784.2013.806483CrossRefPubMed

Chiricozzi A et al (2011) Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131(3):677–687. https://doi.org/10.1038/jid.2010.340CrossRefPubMed

Chu W-M (2013) Tumor necrosis factor. Cancer Lett 328(2):222–225. https://doi.org/10.1016/j.canlet.2012.10.014CrossRefPubMed

Chuah YK et al (2013) Receptor for advanced glycation end products and its involvement in inflammatory diseases. Int J Inflamm 2013:e403460. https://doi.org/10.1155/2013/403460CrossRef

Clunie G et al (2018) Long-term effectiveness of tumour necrosis factor-α inhibitor treatment for psoriatic arthritis in the UK: a multicentre retrospective study. Rheumatol Adv Pract 2(2):rky042. https://doi.org/10.1093/rap/rky042CrossRefPubMedPubMedCentral

Conti F et al (2007) Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 66(10):1393–1397. https://doi.org/10.1136/ard.2007.073569CrossRefPubMedPubMedCentral

Cuff CA et al (1998) Lymphotoxin alpha3 induces chemokines and adhesion molecules: insight into the role of LT alpha in inflammation and lymphoid organ development. J Immunol (baltimore, Md. : 1950) 161(12):6853–6860

Denoble AE et al (2011) Uric acid is a danger signal of increasing risk for osteoarthritis through inflammasome activation. Proc Natl Acad Sci USA 108(5):2088–2093. https://doi.org/10.1073/pnas.1012743108CrossRefPubMedPubMedCentral

Drinda S et al (2005) Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 25(6):411–413. https://doi.org/10.1007/s00296-004-0456-yCrossRefPubMed

Ducharme E, Weinberg JM (2008) Etanercept. Expert Opin Biol Ther 8(4):491–502. https://doi.org/10.1517/14712598.8.4.491CrossRefPubMed

El-Zayat SR, Sibaii H, Mannaa FA (2019) Toll-like receptors activation, signaling, and targeting: an overview. Bull Natl Res Centre 43(1):187. https://doi.org/10.1186/s42269-019-0227-2CrossRef

Fanali G et al (2012) Human serum albumin: from bench to bedside. Mol Aspects Med 33(3):209–290. https://doi.org/10.1016/j.mam.2011.12.002CrossRefPubMed

Fasanmade AA et al (2010) Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 48(5):297–308. https://doi.org/10.5414/cpp48297CrossRefPubMed

Fukami K et al (2015) Receptor for advanced glycation endproducts and progressive kidney disease. Curr Opin Nephrol Hypertens 24(1):54–60. https://doi.org/10.1097/MNH.0000000000000091CrossRefPubMed

Gaens KHJ, Stehouwer CDA, Schalkwijk CG (2013) Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. Curr Opin Lipidol 24(1):4–11. https://doi.org/10.1097/MOL.0b013e32835aea13CrossRefPubMed

Gazzar ME (2015) Immunobiology of S100A8 and S100A9 proteins and their role in acute inflammation and sepsis. Int J Immunol Immunother. https://doi.org/10.23937/2378-3672/1410013CrossRef

Giustizieri ML et al (2001) Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines. J Allergy Clin Immunol 107(5):871–877. https://doi.org/10.1067/mai.2001.114707CrossRefPubMed

Gossec L et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700–712. https://doi.org/10.1136/annrheumdis-2020-217159CrossRefPubMed

Gottlieb AB, Merola JF (2021) Axial psoriatic arthritis: an update for dermatologists. J Am Acad Dermatol 84(1):92–101. https://doi.org/10.1016/j.jaad.2020.05.089CrossRefPubMed

Grant RW, Dixit VD (2015) Adipose tissue as an immunological organ. Obesity (silver Spring, Md.) 23(3):512–518. https://doi.org/10.1002/oby.21003CrossRefPubMed

Gunasekaran MK et al (2013) Inflammation triggers high mobility group box 1 (HMGB1) secretion in adipose tissue, a potential link to obesity. Cytokine 64(1):103–111. https://doi.org/10.1016/j.cyto.2013.07.017CrossRefPubMed

Guzmán-Ruiz R et al (2021) The potential role of the adipokine HMGB1 in obesity and insulin resistance. Novel effects on adipose tissue biology. Mol Cell Endocrinol 536:111417. https://doi.org/10.1016/j.mce.2021.111417CrossRefPubMed

Haddad A, Zisman D (2017) Comorbidities in patients with psoriatic arthritis. Rambam Maimonides Med J 8(1):e0004. https://doi.org/10.5041/RMMJ.10279CrossRefPubMedPubMedCentral

Harper EG et al (2009) Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 129(9):2175–2183. https://doi.org/10.1038/jid.2009.65CrossRefPubMedPubMedCentral

Hellman U et al (2019) Hyaluronan concentration and molecular mass in psoriatic arthritis: biomarkers of disease severity, resistance to treatment, and outcome. Scand J Rheumatol 48(4):284–293. https://doi.org/10.1080/03009742.2019.1577490CrossRefPubMed

Horiuchi T et al (2010) Transmembrane TNF-α: structure, function and interaction with anti-TNF agents. Rheumatology (oxford) 49(7):1215–1228. https://doi.org/10.1093/rheumatology/keq031CrossRefPubMed

Hu Z et al (2015) Role of high-mobility group box 1 protein in inflammatory bowel disease. Inflamm Res 64(8):557–563. https://doi.org/10.1007/s00011-015-0841-xCrossRefPubMed

Huang Q et al (2007) Increased macrophage activation mediated through toll-like receptors in rheumatoid arthritis. Arthritis Rheum 56(7):2192–2201. https://doi.org/10.1002/art.22707CrossRefPubMed

Husni ME (2015) Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am 41(4):677–698. https://doi.org/10.1016/j.rdc.2015.07.008CrossRef

Inciarte-Mundo J et al (2018) Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study. Arthritis Res Ther 20(1):275. https://doi.org/10.1186/s13075-018-1764-zCrossRefPubMedPubMedCentral

Information NC for B. et al (2017) Table 3, Cost comparison table for plaque psoriasis. Canadian Agency for Drugs and Technologies in Health. https://www.ncbi.nlm.nih.gov/books/NBK518589/table/app8.tu1/. Accessed 6 Aug 2021

Jones DH, Kong Y-Y, Penninger JM (2002) Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61(Suppl 2):ii32-39. https://doi.org/10.1136/ard.61.suppl_2.ii32CrossRefPubMedPubMedCentral

Kamata M, Tada Y (2020) Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci 21(5):E1690. https://doi.org/10.3390/ijms21051690CrossRef

Kane D et al (2003) Increased perivascular synovial membrane expression of myeloid-related proteins in psoriatic arthritis. Arthritis Rheum 48(6):1676–1685. https://doi.org/10.1002/art.10988CrossRefPubMed

Kang R et al (2014) HMGB1 in health and disease. Mol Aspects Med. https://doi.org/10.1016/j.mam.2014.05.001CrossRefPubMedPubMedCentral

Ke X et al (2015) Synovial fluid HMGB-1 levels are associated with osteoarthritis severity. Clin Lab 61(7):809–818. https://doi.org/10.7754/clin.lab.2015.141205CrossRefPubMed

Kierdorf K, Fritz G (2013) RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol 94(1):55–68. https://doi.org/10.1189/jlb.1012519CrossRefPubMed

Kopylov U, Seidman E (2016) Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease. Ther Adv Gastroenterol 9(4):513–526. https://doi.org/10.1177/1756283X16638833CrossRef

Kruzliak P et al (2014) Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev 25(1):67–75. https://doi.org/10.1016/j.cytogfr.2014.01.005CrossRefPubMed

Kuo TT et al (2010) Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 30(6):777–789. https://doi.org/10.1007/s10875-010-9468-4CrossRefPubMedPubMedCentral

Li X, Kimberly RP (2014) Targeting the Fc receptor in autoimmune disease. Expert Opin Ther Targets 18(3):335–350. https://doi.org/10.1517/14728222.2014.877891CrossRefPubMedPubMedCentral

Liang S et al (2013) Structural basis for treating tumor necrosis factor α (TNFα)-associated diseases with the therapeutic antibody infliximab. J Biol Chem 288(19):13799–13807. https://doi.org/10.1074/jbc.M112.433961CrossRefPubMedPubMedCentral

Lin E, Calvano SE, Lowry SF (2000) Inflammatory cytokines and cell response in surgery. Surgery 127(2):117–126. https://doi.org/10.1067/msy.2000.101584CrossRefPubMed

Litwinowicz K, Waszczuk E, Gamian A (2021) Advanced glycation end-products in common non-infectious liver diseases: systematic review and meta-analysis. Nutrients 13(10):3370. https://doi.org/10.3390/nu13103370CrossRefPubMedPubMedCentral

Love TJ, Kavanaugh A (2018) Golimumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol 14(11):893–898. https://doi.org/10.1080/1744666X.2018.1524755CrossRefPubMed

Mazzotta A et al (2009) Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. Am J Clin Dermatol 10(5):319–324. https://doi.org/10.2165/11310770-000000000-00000CrossRefPubMed

McCormack WJ, Parker AE, O’Neill LA (2009) Toll-like receptors and NOD-like receptors in rheumatic diseases. Arthritis Res Ther 11(5):243. https://doi.org/10.1186/ar2729CrossRefPubMedPubMedCentral

Mease PJ et al (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet (london, England) 356(9227):385–390. https://doi.org/10.1016/S0140-6736(00)02530-7CrossRefPubMed

Mellor LF et al (2022) Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease. Ann Rheum Dise. https://doi.org/10.1136/annrheumdis-2022-222229CrossRef

Miyagawa I et al (2019) Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis. Rheumatology (oxford) 58(2):336–344. https://doi.org/10.1093/rheumatology/key069CrossRefPubMed

Mosli RH, Mosli HH (2017) Obesity and morbid obesity associated with higher odds of hypoalbuminemia in adults without liver disease or renal failure. Diabetes Metab Syndr Obes 10:467–472. https://doi.org/10.2147/DMSO.S149832CrossRefPubMedPubMedCentral

Mulrennan S et al (2015) The role of receptor for advanced glycation end products in airway inflammation in CF and CF related diabetes. Sci Rep 5(1):8931. https://doi.org/10.1038/srep08931CrossRefPubMedPubMedCentral

Murdaca G et al (2012) Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 32(6):277–279. https://doi.org/10.1089/jir.2011.0120CrossRefPubMed

Nefla M et al (2016) The danger from within: alarmins in arthritis. Nat Rev Rheumatol 12(11):669–683. https://doi.org/10.1038/nrrheum.2016.162CrossRefPubMed

Nilsen J et al (2020) An intact C-terminal end of albumin is required for its long half-life in humans. Commun Biol 3(1):181. https://doi.org/10.1038/s42003-020-0903-7CrossRefPubMedPubMedCentral

Nys G et al (2019) Targeted proteomics reveals serum amyloid A variants and alarmins S100A8-S100A9 as key plasma biomarkers of rheumatoid arthritis. Talanta 204:507–517. https://doi.org/10.1016/j.talanta.2019.06.044CrossRefPubMed

Ogdie A, Weiss P (2015) The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am 41(4):545–568. https://doi.org/10.1016/j.rdc.2015.07.001CrossRef

Ogdie A, Coates LC, Gladman DD (2020) Treatment guidelines in psoriatic arthritis. Rheumatology 59(Supplement_1):i37–i46. https://doi.org/10.1093/rheumatology/kez383CrossRefPubMedPubMedCentral

Ospelt C et al (2008) Overexpression of toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 58(12):3684–3692. https://doi.org/10.1002/art.24140CrossRefPubMed

Papagrigoraki A et al (2017) Advanced Glycation End Products in the Pathogenesis of Psoriasis. Int J Mol Sci 18(11):E2471. https://doi.org/10.3390/ijms18112471CrossRef

Pennica D et al (1984) Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312(5996):724–729. https://doi.org/10.1038/312724a0CrossRefPubMed

Perera C, McNeil HP, Geczy CL (2010) S100 Calgranulins in inflammatory arthritis. Immunol Cell Biol 88(1):41–49. https://doi.org/10.1038/icb.2009.88CrossRefPubMed

Pober JS et al (1987) Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol (baltimore, Md.: 1950) 138(10):3319–3324CrossRef

Pouw J et al (2020) Emerging molecular biomarkers for predicting therapy response in psoriatic arthritis: A review of literature. Clin Immunol (orlando, Fla.) 211:108318. https://doi.org/10.1016/j.clim.2019.108318CrossRef

Prieto-Pérez R et al (2013) Gene polymorphisms that can predict response to anti-TNF therapy in patients with psoriasis and related autoimmune diseases. Pharmacogenomics J 13(4):297–305. https://doi.org/10.1038/tpj.2012.53CrossRefPubMed

Pyzik M et al (2019) The neonatal Fc receptor (FcRn): a misnomer? Front Immunol 10:1540. https://doi.org/10.3389/fimmu.2019.01540CrossRefPubMedPubMedCentral

Ryckman C et al (2003) Proinflammatory activities of S100: proteins S100A8, S100A9, and S100A8/A9 induce neutrophil chemotaxis and adhesion. J Immunol (baltimore, Md.: 1950) 170(6):3233–3242. https://doi.org/10.4049/jimmunol.170.6.3233CrossRef

Sakkas LI, Zafiriou E, Bogdanos DP (2019) Mini review: new treatments in psoriatic arthritis. Focus on the IL-23/17 Axis. Front Pharmacol 10:872. https://doi.org/10.3389/fphar.2019.00872CrossRefPubMedPubMedCentral

Schenten V et al (2018) Secretion of the phosphorylated form of S100A9 from neutrophils is essential for the proinflammatory functions of extracellular S100A8/A9. Front Immunol 9:447. https://doi.org/10.3389/fimmu.2018.00447CrossRefPubMedPubMedCentral

Schön MP (2019) Adaptive and Innate Immunity in Psoriasis and Other Inflammatory Disorders. Front Immunol. https://doi.org/10.3389/fimmu.2019.01764 (Accessed: 19 May 2022)CrossRefPubMedPubMedCentral

Sedger LM, McDermott MF (2014) TNF and TNF-receptors: from mediators of cell death and inflammation to therapeutic giants—past, present and future. Cytokine Growth Factor Rev 25(4):453–472. https://doi.org/10.1016/j.cytogfr.2014.07.016CrossRefPubMed

Sheikh G et al (2015) Comparison of levels of serum copper, zinc, albumin, globulin and alkaline phosphatase in psoriatic patients and controls: a hospital based casecontrol study. Indian Dermatol Online J 6(2):81–83. https://doi.org/10.4103/2229-5178.153006CrossRefPubMedPubMedCentral

Soeters PB, Wolfe RR, Shenkin A (2019) Hypoalbuminemia: Pathogenesis and Clinical Significance. JPEN 43(2):181–193. https://doi.org/10.1002/jpen.1451CrossRef

Stapleton NM et al (2019) Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge. Sci Rep 9(1):7363. https://doi.org/10.1038/s41598-019-40731-2CrossRefPubMedPubMedCentral

Sumarac-Dumanovic M et al (2009) Increased activity of interleukin-23/interleukin-17 proinflammatory axis in obese women. Int J Obes (2005) 33(1):151–156. https://doi.org/10.1038/ijo.2008.216CrossRef

Sun L, Liu W, Zhang L-J (2019) The role of toll-like receptors in skin host defense, psoriasis, and atopic dermatitis. J Immunol Res 2019:1824624. https://doi.org/10.1155/2019/1824624CrossRefPubMedPubMedCentral

Taniguchi N et al (2018) HMGB proteins and arthritis. Hum Cell 31(1):1–9. https://doi.org/10.1007/s13577-017-0182-xCrossRefPubMed

Tesmer LA et al (2008) Th17 cells in human disease. Immunol Rev 223:87–113. https://doi.org/10.1111/j.1600-065X.2008.00628.xCrossRefPubMedPubMedCentral

Veale DJ, Fearon U (2018) The pathogenesis of psoriatic arthritis. Lancet (london, England) 391(10136):2273–2284. https://doi.org/10.1016/S0140-6736(18)30830-4CrossRefPubMed

Veering BT et al (1990) The effect of age on serum concentrations of albumin and alpha 1-acid glycoprotein. Br J Clin Pharmacol 29(2):201–206CrossRefPubMedPubMedCentral

Vlassara H, Striker GE (2013) Advanced glycation endproducts in diabetes and diabetic complications. Endocrinol Metab Clin North Am 42(4):697–719. https://doi.org/10.1016/j.ecl.2013.07.005CrossRefPubMed

Wang Y et al (2016) The role of HMGB1 in the pathogenesis of type 2 diabetes. J Diabetes Res 2016:2543268. https://doi.org/10.1155/2016/2543268CrossRefPubMedPubMedCentral

Wang S et al (2018) S100A8/A9 in inflammation. Front Immunol 9:1298. https://doi.org/10.3389/fimmu.2018.01298CrossRefPubMedPubMedCentral

Ware CF (2005) Network communications: lymphotoxins, LIGHT, and TNF. Annu Rev Immunol 23:787–819. https://doi.org/10.1146/annurev.immunol.23.021704.115719CrossRefPubMed

Wei M et al (2013) Increased thymosin β4 levels in the serum and SF of knee osteoarthritis patients correlate with disease severity. Regul Pept 185:34–36. https://doi.org/10.1016/j.regpep.2013.06.011CrossRefPubMed

Winterfield LS, Menter A (2004) Infliximab. Dermatol Ther 17(5):409–426. https://doi.org/10.1111/j.1396-0296.2004.04044.xCrossRefPubMed

Winthrop KL et al (2019) Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Ann Rheum Dis 78(7):872–878. https://doi.org/10.1136/annrheumdis-2018-214280CrossRefPubMed

Yang D, Han Z, Oppenheim JJ (2017) Alarmins and immunity. Immunol Rev 280(1):41–56. https://doi.org/10.1111/imr.12577CrossRefPubMedPubMedCentral

Yang J et al (2018) Calcium-binding proteins S100A8 and S100A9: investigation of their immune regulatory effect in myeloid cells. Int J Mol Sci 19(7):1833. https://doi.org/10.3390/ijms19071833CrossRefPubMedPubMedCentral

Zelová H, Hošek J (2013) TNF-α signalling and inflammation: interactions between old acquaintances. Inflamm Res 62(7):641–651. https://doi.org/10.1007/s00011-013-0633-0CrossRefPubMed

Zhang H et al (2021) Comparative effectiveness of biologics and targeted therapies for psoriatic arthritis. RMD Open 7(1):e001399. https://doi.org/10.1136/rmdopen-2020-001399CrossRefPubMedPubMedCentral

Title: Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors
Authors: Anaïs Makos
J. H. Kuiper
O. Kehoe
R. Amarasena
Publication date: 12-12-2022
Publisher: Springer International Publishing
Keywords: Etanercept
Infliximab
TNF-Inhibitors
Vulgar Psoriasis
Psoriatic Arthritis
Cytokines
Biomarkers
Published in: Inflammopharmacology / Issue 1/2023
Print ISSN: 0925-4692
Electronic ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-022-01092-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Psoriatic arthritis: review of potential biomarkers predicting response to TNF inhibitors

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Effects of Quinoa (Chenopodium quinoa) on inflammatory mediators: a systematic review of preclinical studies

Exploring the possible mechanism involved in the anti-nociceptive effect of β-sitosterol: modulation of oxidative stress, nitric oxide and IL-6

Gastroprotective and anti-Helicobacter pylori potentials of essential oils from the oleoresins of Araucaria bidwillii and Araucaria heterophylla

A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection

MicroRNAs-mediated regulation pathways in rheumatic diseases

Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases